298380 - ABL Bio Inc.

298380 Summary

Biopharma

Stock Price & Overview

₩71,400 +3,800 (+5.62%) Close · Sep 4, 2026 KST

KOSDAQ | ₩KRW | Close: ₩71,400 ≈ US$51 · Market cap ₩4.0tn (≈ $2.9bn)

298380 Financial Statements

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Revenue	79.3	33.4	65.5	67.3	5.3	8.1
Operating Income	-40.4	-59.4	-2.6	0.9	-52.3	-59.6
Finance Income	6.0	5.5	7.1	6.6	8.6	9.7
Finance Costs	3.0	1.9	5.8	7.0	1.1	4.4
Pretax Income	-37.9	-55.5	-2.6	3.2	-43.6	-55.6
Income Tax Expense	0.0	0.0	0.0	—	—	—
Net Income	-37.9	-55.5	-2.6	3.2	-43.6	-55.6
Total Comprehensive Income	-37.2	-55.5	-3.1	3.4	-43.5	-55.8

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Total Assets	280.9	232.0	160.1	185.2	65.5	99.9
Current Assets	176.1	144.2	75.5	80.5	45.5	71.9
Cash & Cash Equivalents	112.0	56.3	28.1	25.1	21.6	40.7
Trade Receivables	—	—	—	0.5	0.2	1.2
Non-current Assets	104.9	87.8	84.6	104.6	20.0	28.0
Property, Plant & Equipment	101.1	85.4	76.0	6.7	3.3	4.1
Intangible Assets	2.9	2.4	2.5	2.6	2.6	2.7
Total Liabilities	124.2	64.7	86.1	115.7	9.5	9.2
Current Liabilities	123.5	63.4	41.8	72.2	8.8	8.0
Non-current Liabilities	0.7	1.3	44.3	43.5	0.7	1.3
Total Equity	156.7	167.3	74.1	69.5	56.0	90.7
Share Capital	27.6	27.0	23.9	23.9	23.6	23.1
Retained Earnings	-436.2	-398.3	-342.3	-339.1	-342.5	-299.1

Breakdown ₩ bn	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Cash from Operating Activities	-41.3	-69.4	-28.4	72.1	-40.6	-47.3
Cash from Investing Activities	62.1	-47.2	29.9	-71.2	20.2	-3.6
Cash from Financing Activities	32.5	144.6	1.4	4.6	0.3	0.6
Net Change in Cash	53.4	28.0	3.0	—	—	—

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Revenue	19.7	13.1	0.0	1.4	75.7	2.2	9.1	7.9	8.4	7.9
Operating Income	-16.8	-17.2	-29.7	-22.4	40.7	-29.0	-19.1	-14.7	-11.3	-14.3
Finance Income	2.3	4.6	2.6	1.2	1.1	1.1	0.5	1.8	1.0	2.2
Finance Costs	0.5	2.0	0.5	0.1	2.1	0.2	0.5	0.2	1.1	0.1
Pretax Income	-15.0	-14.7	-28.2	-21.3	39.8	-28.1	-19.0	-13.1	-11.4	-12.0
Income Tax Expense	0.0	—	—	—	—	—	—	—	—	—
Net Income	-15.0	-14.7	-28.2	-21.3	39.8	-28.1	-19.0	-13.1	-11.4	-12.0
Total Comprehensive Income	-13.8	-12.2	-27.4	-21.2	39.5	-28.2	-19.1	-13.3	-11.3	-11.8

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Total Assets	273.7	298.1	280.9	235.0	244.2	210.7	232.0	244.6	120.7	140.8
Current Assets	169.9	193.5	176.1	130.1	139.9	112.6	144.2	156.9	36.1	56.5
Cash & Cash Equivalents	165.0	186.7	112.0	124.4	132.8	23.2	56.3	150.4	1.0	13.9
Trade Receivables	—	—	—	1.1	0.6	2.4	1.7	1.1	1.0	0.3
Non-current Assets	103.9	104.6	104.9	104.9	104.3	98.1	87.8	87.7	84.6	84.3
Property, Plant & Equipment	100.4	101.0	101.1	101.9	101.3	95.2	85.4	83.3	79.9	77.6
Intangible Assets	3.1	3.0	2.9	2.9	2.8	2.8	2.4	2.4	2.5	2.5
Total Liabilities	99.8	114.8	124.2	52.8	60.4	67.7	64.7	63.8	67.6	77.0
Current Liabilities	99.0	114.0	123.5	51.5	59.4	66.1	63.4	20.1	23.4	32.7
Non-current Liabilities	0.8	0.8	0.7	1.3	0.9	1.6	1.3	43.7	44.2	44.2
Total Equity	173.9	183.3	156.7	182.2	183.8	143.0	167.3	180.8	53.2	63.8
Share Capital	28.0	28.0	27.6	27.6	27.2	27.2	27.0	26.9	24.0	23.9
Retained Earnings	-465.4	-450.7	-436.2	-407.9	-386.7	-426.5	-398.3	-378.9	-365.7	-354.3

Breakdown ₩ bn	2026 Q2	2026 Q1	2025 Q4	2025 Q3	2025 Q2	2025 Q1	2024 Q4	2024 Q3	2024 Q2	2024 Q1
Cash from Operating Activities	-23.4	32.8	-23.6	-27.6	38.3	-28.4	-15.6	-18.0	-18.4	-17.5
Cash from Investing Activities	-0.8	0.8	-2.7	0.2	72.1	-7.5	-83.2	27.7	5.1	3.2
Cash from Financing Activities	-0.1	36.9	12.0	18.1	-0.3	2.8	4.4	139.7	0.8	-0.3
Net Change in Cash	-24.3	70.6	—	—	—	—	—	—	—	—

Consolidated (CFS), from DART. 6 fiscal years and 10 quarters. Accounts matched on IFRS account_id, not Korean labels, so the same line holds across years where the Korean wording changed. Quarterly figures are three-month values: income quarters from DART's three-month column, cash-flow quarters differenced from DART's cumulative figures, and Q4 as annual minus nine-month cumulative.

298380 Growth

FY2025 ₩bn	Latest	1-yr	3-yr CAGR	5-yr CAGR	10-yr CAGR
Revenue	79.3	+137.6%	+5.6%	+57.8%	—
Operating income	-40.4	—	—	—	—
Net income	-37.9	—	—	—	—
EPS	₩-677	—	—	—	—
Operating cash flow	-41.3	—	—	—	—
Shareholders' equity	156.7	-6.3%	+31.1%	+11.6%	—

Compound annual growth from the DART annual statements on this page. n/m where either end of the period is a loss or missing. EPS uses today's share count for every year.

298380 Profitability

Ratio	FY2025	FY2024	FY2023	FY2022	FY2021	FY2020
Operating margin	-50.9%	-177.8%	-4.0%	1.3%	-981.0%	-736.0%
Net margin	-47.7%	-166.2%	-4.0%	4.8%	-816.9%	-686.1%
Return on equity	-23.4%	-46.0%	-3.7%	5.1%	-59.4%	-61.3%
Return on assets	-14.8%	-28.3%	-1.5%	2.6%	-52.7%	-55.7%
Operating cash flow / revenue	-52.0%	-207.8%	-43.3%	107.2%	-761.5%	-583.6%

Margins divide by revenue for the same year. Return on equity and assets divide net income by the average of that year's and the prior year's balance, as DART reports them (consolidated, including minority interests).

Similar to 298380

Symbol	Last Price
128940Hanmi Pharm. Co., Ltd.	₩473,500 +2.8%
000100Yuhan Corporation	₩81,400 +0.0%
028300HLB Co., Ltd.	₩33,750 +2.9%
000250Samchundang Pharm	₩157,000 +1.0%
087010Peptron, Inc.	₩157,300 +7.3%
141080LigaChem Biosciences Inc.	₩92,000 +4.2%
145020Hugel, Inc.	₩244,000 +1.5%
302440SK Bioscience Co., Ltd.	₩37,900 +0.4%
009420Hanall Biopharma Co., Ltd.	₩54,700 +1.5%
310210Voronoi, Inc.	₩153,000 +3.9%

Compare all 48 in Biopharma

What a US investor should know

Trading hours09:00–15:30 KST — 20:00–02:30 US Eastern the night before.
Daily limitKorean stocks can move at most ±30% in a session before trading halts.
Getting exposureKRX shares are not directly tradable in most US brokerage accounts. The usual routes are Korea ETFs or an international account.
ReportingKorean issuers file to DART, not the SEC. Half-year and quarterly reports land about 45 days after period end.